Annual report pursuant to Section 13 and 15(d)

Acquisition of Ohr Pharmaceutical, Inc. - Net assets acquired (Details)

v3.19.3.a.u2
Acquisition of Ohr Pharmaceutical, Inc. - Net assets acquired (Details) - USD ($)
12 Months Ended
Jul. 12, 2019
Sep. 30, 2019
Acquisition of Ohr Pharmaceutical, Inc.    
Cash and cash equivalents $ 752,419  
Prepaid expenses and other current assets 115,769  
Investment in DepYmed 586,418  
Intangible assets 250,000  
Warrant liability (470,093)  
Accounts payable and accrued expenses (493,055)  
Fair value of net assets acquired 741,458  
Research and development expense- License acquired cost of Ohr Acquisition 11,920,450 $ (11,920,450)
Total cost of the Ohr acquisition $ 12,661,908